Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 2/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.39 |
| ▸ | KCNJ6 | P48051 | 1/20 | 0.32 |
| ▸ | KCNJ5 | P48544 | 1/20 | 0.32 |
| ▸ | KCNJ3 | P48549 | 1/20 | 0.32 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.31 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.31 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.30 |
| ▸ | CCR8 | P51685 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4696979 | 0.83 | HSD11B1 (0.51) | HSD11B1KCNH2HRH3KCNJ6KCNJ5 | |
| SCHEMBL4696969 | 0.82 | HSD11B1 (0.50) | HSD11B1KCNH2HRH3KCNJ6KCNJ5 | |
| SCHEMBL3744296 | 0.81 | HSD11B1 (0.47) | HSD11B1HRH3S1PR5 | |
| SCHEMBL3741588 | 0.79 | HSD11B1 (0.50) | HSD11B1 | |
| SCHEMBL14143549 | 0.79 | HSD11B1 (0.50) | HSD11B1 | |
| SCHEMBL3743299 | 0.78 | HSD11B1 (0.41) | HSD11B1S1PR5 | |
| SCHEMBL3744360 | 0.78 | HSD11B1 (0.60) | HSD11B1CCR8 | |
| SCHEMBL3746550 | 0.73 | HSD11B1 (0.50) | HSD11B1 | |
| SCHEMBL4697260 | 0.73 | HSD11B1 (0.48) | HSD11B1KCNH2HRH3KCNJ6KCNJ5 | |
| SCHEMBL4696670 | 0.71 | HSD11B1 (0.51) | HSD11B1KCNH2HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7834194-B2 | Metabolic disorders; antidiabetic agents; hypoglycemic agents; obesity; hypotensive agents | ELI LILLY AND COMPANY (US) | 2010-11-16 | — | — | US | claimed |
| US-20080207691-A1 | Cycloalkyl Lactam Derivatives As Inhibitors Of 11-Beta-Hydroxysteroid Dehydrogenase 1 | ELI LILLY AND COMPANY | 2008-08-28 | — | — | US | claimed |
| EP-1830840-B1 | CYCLOALKYL LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | LILLY CO ELI (US) | 2008-07-16 | — | — | EP | claimed |
| EP-1830840-A1 | CYCLOALKYL LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | ELI LILLY AND COMPANY (US) | 2007-09-12 | — | — | EP | claimed |
| WO-2006068991-A1 | CYCLOALKYL LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | ELI LILLY AND COMPANY (US) | 2006-06-29 | — | — | WO | claimed |
| US-7834194-B2 | Metabolic disorders; antidiabetic agents; hypoglycemic agents; obesity; hypotensive agents | ELI LILLY AND COMPANY (US) | 2010-11-16 | — | — | US | disclosed |
| US-7834194-B2 | Metabolic disorders; antidiabetic agents; hypoglycemic agents; obesity; hypotensive agents | ELI LILLY AND COMPANY (US) | 2010-11-16 | — | — | US | disclosed |
| US-7834194-B2 | Metabolic disorders; antidiabetic agents; hypoglycemic agents; obesity; hypotensive agents | ELI LILLY AND COMPANY (US) | 2010-11-16 | — | — | US | disclosed |
| US-20080207691-A1 | Cycloalkyl Lactam Derivatives As Inhibitors Of 11-Beta-Hydroxysteroid Dehydrogenase 1 | ELI LILLY AND COMPANY | 2008-08-28 | — | — | US | disclosed |
| US-20080207691-A1 | Cycloalkyl Lactam Derivatives As Inhibitors Of 11-Beta-Hydroxysteroid Dehydrogenase 1 | ELI LILLY AND COMPANY | 2008-08-28 | — | — | US | disclosed |
| US-20080207691-A1 | Cycloalkyl Lactam Derivatives As Inhibitors Of 11-Beta-Hydroxysteroid Dehydrogenase 1 | ELI LILLY AND COMPANY | 2008-08-28 | — | — | US | disclosed |
| EP-1830840-B1 | CYCLOALKYL LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | LILLY CO ELI (US) | 2008-07-16 | — | — | EP | disclosed |
| EP-1830840-B1 | CYCLOALKYL LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | LILLY CO ELI (US) | 2008-07-16 | — | — | EP | disclosed |
| EP-1830840-A1 | CYCLOALKYL LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | ELI LILLY AND COMPANY (US) | 2007-09-12 | — | — | EP | disclosed |
| WO-2006068991-A1 | CYCLOALKYL LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | ELI LILLY AND COMPANY (US) | 2006-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207691-A1 | Cycloalkyl Lactam Derivatives As Inhibitors Of 11-Beta-Hydroxysteroid Dehydrogenase 1 | HSD11B1, HSD17B1, HSD17B10 | HSD11B1 1/4885KCNH2 2635/4885HRH3 836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.